By day 29, the SLIT3-expressing group exhibited significant tumor growth suppression compared to the Ctrl group (Fig. 5B, C), demonstrating the in vivo capacity of SLIT3 to suppress tumor growth. This evidence concerns the gene SLIT3 and neoplasm.